ASH Annual Meeting

Oncology Times - OncTimes Talk
21/07/2009 26 min
ASH Annual Meeting

Listen "ASH Annual Meeting"

Descargar episodio Ver en sitio original

Episode Synopsis

Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL patients with rituximab added to standard chemotherapy). Offering perspective are Kenneth Kaushansky, Linda Burns, and George Canellos.

More episodes of the podcast Oncology Times - OncTimes Talk

From Ironman to Advocate: Tom Hulsey’s Journey Through Prostate Cancer and Purpose 01/08/2025
Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test 17/07/2025
Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield 01/07/2025
Defying the Odds: Katie Coleman's Journey from Diagnosis to Advocacy 02/06/2025
Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing 28/05/2025
Transforming colorectal cancer management with tumor informed ctDNA testing 22/05/2025
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey 02/05/2025
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk 27/03/2025
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 03/03/2025
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 03/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA